- Home
- GLAD vs AUTL Comparison
GLAD vs AUTL Comparison
Compare GLAD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- AUTL
- Stock Information
- Founded
- GLAD 2001
- AUTL 2014
- Country
- GLAD United States
- AUTL United Kingdom
- Employees
- GLAD N/A
- AUTL N/A
- Industry
- GLAD Finance/Investors Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLAD Finance
- AUTL Health Care
- Exchange
- GLAD Nasdaq
- AUTL Nasdaq
- Market Cap
- GLAD 611.4M
- AUTL 609.4M
- IPO Year
- GLAD N/A
- AUTL 2018
- Fundamental
- Price
- GLAD $27.38
- AUTL $2.29
- Analyst Decision
- GLAD Hold
- AUTL Strong Buy
- Analyst Count
- GLAD 1
- AUTL 3
- Target Price
- GLAD $23.00
- AUTL $10.20
- AVG Volume (30 Days)
- GLAD 133.9K
- AUTL 1.8M
- Earning Date
- GLAD 02-03-2025
- AUTL 11-12-2024
- Dividend Yield
- GLAD 7.24%
- AUTL N/A
- EPS Growth
- GLAD 89.73
- AUTL N/A
- EPS
- GLAD 4.34
- AUTL N/A
- Revenue
- GLAD $96,621,000.00
- AUTL $10,091,000.00
- Revenue This Year
- GLAD $3.67
- AUTL $1,000.24
- Revenue Next Year
- GLAD $14.13
- AUTL $267.86
- P/E Ratio
- GLAD $6.31
- AUTL N/A
- Revenue Growth
- GLAD 11.79
- AUTL 82.71
- 52 Week Low
- GLAD $19.20
- AUTL $2.20
- 52 Week High
- GLAD $28.40
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- GLAD 55.87
- AUTL 28.90
- Support Level
- GLAD $27.22
- AUTL $2.44
- Resistance Level
- GLAD $28.40
- AUTL $2.97
- Average True Range (ATR)
- GLAD 0.62
- AUTL 0.18
- MACD
- GLAD -0.09
- AUTL -0.04
- Stochastic Oscillator
- GLAD 51.20
- AUTL 8.82
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.